Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04453423

Combination Chemotherapy With or Without Anlotinib in the Maintenance Treatment of Non-Squamous Non-Small Cell Lung Cancer.

Non-squamous Non-small-cell Lung Cancer Clinical Trial

Official title:
A Study of the Effect of Anlotinib, Pemetrexed or the Combination As Maintenance Therapy for Patients With Non-Squamous Non-Small Cell Lung Cancer.

Clinical Trial Summary

This study will compare maintenance therapy with anlotinib plus pemetrexed versus pemetrexed or anlotinib alone, in patients with Non-squamous Non-small cell lung cancer who have not progressed during first-line therapy with anlotinib + pemetrexed + carboplatin. The primary endpoint of the study is progression-free survival (PFS); the secondary endpoints are disease control rate (DCR), objective response rate (ORR) and overall survival (OS).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04453423
Study type Interventional
Source The First Affiliated Hospital with Nanjing Medical University
Contact Renhua Guo, MD
Phone 025-68136360
Email rhguo@njmu.edu.cn
Status Not yet recruiting
Phase Phase 2
Start date July 1, 2020
Completion date July 1, 2022
View Details
See also
  Status Clinical Trial Phase
Completed NCT04504916 - A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Solid Tumors (MK-2140-002) Phase 2
Not yet recruiting NCT05849246 - The Study of Tusamitamab Ravtansine (IBI126) Combined With Sintilimab and Tusamitamab Ravtansine (IBI126) Combined With Sintilimab Plus Platinum-based Chemotherapy and Pemetrexed in Subjects With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC) Phase 2
Active, not recruiting NCT04396457 - Pembrolizumab Plus Pemetrexed for Elderly Patients With Non-Sq NSCLC With PD-L1 < 50%: CJLSG1901 Phase 2
Recruiting NCT05338619 - A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy Phase 2
Terminated NCT04265534 - KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC Phase 2
Active, not recruiting NCT05258279 - Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations Phase 2
Terminated NCT04173338 - Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma Phase 1
Terminated NCT04698681 - NGS Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes for the KEAPSAKE (CX-839-014) Trial
Active, not recruiting NCT04211090 - Camrelizumab With AC in Patients With Brain Metastases of Driven Gene-negative,NSCLC Phase 2
Recruiting NCT04619433 - A Study to Evaluate SHR-1210 in Combination With Famitinib Plus Chemotherapy in Subjects With NSCLC. Phase 3
Recruiting NCT04084717 - Study of Crizotinib for ROS1 and MET Activated Lung Cancer Phase 2
Recruiting NCT04958811 - Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC Phase 2
Completed NCT00152477 - A Study of Paclitaxel/Carboplatin With or Without CDP791 in Patients With Lung Cancer Phase 2
Completed NCT04012619 - Anlotinib Hydrochloride Combined With AP in Stage IIIB/IIIC/IV Non-squamous Non-small-cell Lung Cancer Phase 1
Recruiting NCT05403554 - A Study of NI-1801 in Patients With Mesothelin Expressing Solid Cancers Phase 1
Completed NCT05318443 - A Study Exploring Efficacy of SIBP04 in Subjects With Non-squamous Non-small Cell Lung Cancer Phase 3